6 , 58 Through integrated omics analysis of more than 1000 CCL datasets, transcriptomic and proteomic signatures (i.e., the estrogen response and P53 pathway) exhibited a highly significant positive correlation with EGFRi sensitivity, even in CCLs with wildtype EGFR.
← all excerpts
Systematic omics analysis identifies CCR6 as a therapeutic target to overcome cancer resistance to EGFR inhibitors.
1
—
—